Company Overview and News
Facebook (FB - Free Report) recently announced that the company will restrain from physically sending its employees to promote the use of the platform for political campaigns. Facebook had offered personalized services before the 2016 elections, detailing how candidates and political parties can use the social media platform to better reach voters. The company now intends to provide free and common information online globally to all the people and parties interested in creating awareness about their political campaigns.
FB AT EOG ATP GOOGL SRE TWTR VSH SPG APRWF
We have to wait another few weeks before Q3 earnings season really takes the spotlight, but the reporting cycle has gotten underway already, with results from 8 S&P 500 members out and another 8 index members on deck to report this week. All of these early reporters have fiscal quarters ending in August, but they get counted as part of the September-quarter tally.
KBH NKE CUKPF KMX CCL ACN CCL SPG CUK EOG
Property and casualty insurer The Allstate Corporation (ALL - Free Report) expects to incur $186 million, pre-tax ($147 million after-tax) catastrophe loss for the month of August. These losses can be attributed to 16 events at an estimated cost of $137 million, pre-tax. The rest of the loss pertains to unfavorable reserve reestimates of prior-reported catastrophe losses.
AT HIG HGH 8685 GJT AVF AIG EOG ALL ATP SRE SPG APRWF
Property and casualty insurance industry has again endured the wrath of Mother Nature with the advent of hurricanes Florence and Lane. The third quarter of a year generally bears the brunt of unprecedented catastrophes as it marks the peak of hurricane season. Nonetheless, factors like better pricing, favorable rate environment, sturdy capital surplus, strengthening labor market and improving employment scenario poise the industry well for improved performances.
HALL TRV AT PGR EOG ATP SRE SPG Y APRWF
Shares of ACADIA Pharmaceuticals Inc. (ACAD - Free Report) soared 26.6% after the FDAissued a clear statement reaffirming the positive benefit-risk profile of Nuplazid (pimavanserin) for patients with Parkinson’s disease psychosis. However, shares of the company have decreased 36.5% year to date compared with the industry’s decline of 3.5%.
REGN GILD AT LGNDZ EOG ACAD ATP SRE LGNZZ LGND LGNYZ LGNXZ SPG APRWF
Disney (DIS - Free Report) , according to reports, is working with its subsidiary, Marvel Studios, on a short series for its streaming service, per Variety. The service, set to launch in late 2019, will comprise a limited series based on popular characters from Marvel Cinematic Universe (MCU). The series will be produced by Marvel Studios and Kevin Feige, a key person with the studios, is expected to be part of the development.
ATP SRE AAPL AT NFLX SPG APRWF EOG
On Sep 21, we issued an updated research report on Koninklijke Philips N.V. (PHG - Free Report) . The company reports operations primarily under three segments - Personal Health businesses (accounted for 41.1% of total sales in 2017), Diagnosis & Treatment businesses (38.8%), and Connected Care & Health Informatics businesses (17.8%). The company also identifies HealthTech Other and Legacy Items. Philips is gradually evolving as a healthcare company, having augmented its presence in the domain, primarily driven by an expanding portfolio.
AT PAYC EOG ATP SRE VSH SPG NTAP PHG APRWF
Amazon (AMZN - Free Report) may be rapidly gaining digital advertising market share, but it also has a comprehensive physical store expansion up its sleeve. So despite the valuation, analysts continue to raise their price targets-
WFCNP FB AT WMT LNSTY WFC EOG ATP GOOGL SRE MSFT SPG APRWF
In the latest trading session, UnitedHealth Group (UNH - Free Report) closed at $266.70, marking a +0.11% move from the previous day. The stock outpaced the S&P 500's daily loss of 0.04%. Meanwhile, the Dow gained 0.33%, and the Nasdaq, a tech-heavy index, lost 0.51%.
AOBC SPG CLBS UNH EOG
AbbVie (ABBV - Free Report) closed the most recent trading day at $92.05, moving -0.51% from the previous trading session. The stock lagged the S&P 500's daily loss of 0.04%. Meanwhile, the Dow gained 0.33%, and the Nasdaq, a tech-heavy index, lost 0.51%.
AOBC ABBV SPG CLBS ABBV EOG
Pfizer (PFE - Free Report) closed the most recent trading day at $44.06, moving +0.71% from the previous trading session. The stock outpaced the S&P 500's daily loss of 0.04%. Meanwhile, the Dow gained 0.33%, and the Nasdaq, a tech-heavy index, lost 0.51%.
AOBC SPG CLBS PFE EOG
2018-09-21 zacks - 1
In the latest trading session, Snap (SNAP - Free Report) closed at $9.14, marking a -0.71% move from the previous day. The stock lagged the S&P 500's daily loss of 0.04%. Meanwhile, the Dow gained 0.33%, and the Nasdaq, a tech-heavy index, lost 0.51%.
AOBC SPG CLBS SNAP EOG
2018-09-21 zacks - 2
Square (SQ - Free Report) closed the most recent trading day at $85.30, moving -1.53% from the previous trading session. The stock lagged the S&P 500's daily loss of 0.04%. Elsewhere, the Dow gained 0.33%, while the tech-heavy Nasdaq lost 0.51%.
SQ AOBC SPG CLBS EOG
Tencent Holding (TCEHY - Free Report) closed at $42.77 in the latest trading session, marking a +1.86% move from the prior day. This move outpaced the S&P 500's daily loss of 0.04%. At the same time, the Dow added 0.33%, and the tech-heavy Nasdaq lost 0.51%.
TCEHY AOBC SPG TCTZF CLBS EOG
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to SPG / Simon Property Group, Inc. on message board site Silicon Investor.
as of ET